QuiaPEG

Newsroom

Apr 07, 2020

QuiaPEG Pharmaceuticals Holding AB (publ) ("QuiaPEG"), which develops versions of clinically validated or already approved drugs, today announced it has signed an agreement with the German company Celares GmbH to develop an optimized process suitable for large scale production of products based onQuiaPEG’sUni-Qleaver technology, including QPG-1029 according to current Good Manufacturing Practice (cGMP).

Download press release (PDF)
Contact
QuiaPEG Pharmaceuticals Holding AB

Virdings Allé 32 B
754 50 Uppsala
Sweden
+46 (0) 70 693 12 53
info@quiapeg.com

User terms & privacy policy
Send a message